AwardTape · Defense awards · Medical · Drugs and biologicals · HT001426FE062
HT001426FE062: $245K BPA call to Sofie Co
Sofie Co holds a BPA call from Defense Health Agency with $245K obligated since Oct 2023, against a ceiling of $245K. Latest action Jun 4, 2026.
Acquisition of neuraceq (florbetaben f18).
| PIID | HT001426FE062 |
|---|---|
| Type | BPA call |
| Parent award | HT001424A0002 |
| Company | Sofie Co |
| Agency | Defense Health Agency |
| Contracting office | DEFENSE HEALTH AGENCY |
| Category | Medical · Drugs and biologicals |
| PSC | 6505 DRUGS AND BIOLOGICALS |
| NAICS | 325412 PHARMACEUTICAL PREPARATION MANUFACTURING |
| Obligated since Oct 2023 | $245K |
| Total obligated (lifetime) | $245K |
| Ceiling (base and all options) | $245K |
| Base date | Jun 4, 2026 |
| Latest action | Jun 4, 2026 |
| End date | May 26, 2027 |
| Actions since Oct 2023 | 1 |
| Pricing | Firm fixed price |
| Competition | Not competed under simplified acquisition |
| Place of performance | MD |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial